12:00 AM
 | 
Aug 26, 2002
 |  BioCentury  |  Tools & Techniques

Picking the right seat in cancer

C-myc is an oncogene implicated in inducing genes involved in proliferation, while repressing genes involved in growth arrest. Companies like AVI BioPharma Inc. have been developing antisense inhibitors of the gene to treat cancers and other proliferative disorders. But a paper published in last week's Proceedings of the National Academy of Sciences describes a new way of targeting the oncogene based on the formation of a regulatory element within c-myc's promoter region.

Researchers from Cyternex Inc. (San Diego, Calif.) showed that transcription of c-myc is...

Read the full 418 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >